ClearOne, Inc. (NASDAQ:CLRO) shares jumped 98.37% to $7.30 in after-hours trading Wednesday following a Securities and Exchange Commission filing that revealed fresh progress on its planned merger with clinical-stage biopharmaceutical company Vivani Medical, Inc.‘s Cortigent, Inc. unit.
Stockholder Vote Clears Path for Merger Share Issuance
According to the SEC filing, majority stockholder First Finance Ltd. approved by written consent the issuance of 12.5 million common shares tied to the merger, which exceeds 20% of ClearOne’s outstanding shares and triggers a change-of-control provision under Nasdaq listing rules.
First Finance held 1.64 million shares as of the Jul. 31 record date, giving it about 61.3% of ClearOne’s voting power. That majority is enough to approve the measures through written consent. However, the share issuance will not take effect until 20 days after ClearOne sends the required disclosure statement to shareholders.
The filing noted that ClearOne will also adopt its 2026 Omnibus Incentive Plan, a company-wide equity compensation program, with further details to be disclosed in a forthcoming filing.
Warrant Cancellation and CFO Retention Deepen Deal Certainty
The Utah-based technology company canceled First Finance’s warrants to buy 437,500 shares. In addition, the company signed Chief Financial Officer Simon Brewer to a new employment agreement that takes effect when the deal closes. Under the agreement, Brewer will receive a base salary of $300,000 and 200,000 stock options.
Trading Metrics, Technical Analysis
ClearOne has a market value of about $9.85 million. Over the past 52 weeks, its stock has traded as high as $16.50 and as low as $2.72. The company has approximately 2.68 million shares outstanding.
CLRO has a Relative Strength Index (RSI) of 38.48.
On Wednesday, ClearOne saw elevated trading activity, with 8.55 million shares changing hands, about 1.3 times its average daily volume of 6.50 million shares.
Over the past 12 months, the stock has fallen 22.20%.
Currently, the stock is trading about 7% above its 52-week low, placing it in the lower end of its 52-week trading range.
Price Action: CLRO closed the regular session on Wednesday at $3.68, down 8.68%, according to Benzinga Pro data.
Benzinga’s Edge Stock Rankings indicate CLRO stock has a negative price trend across all time frames.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Pavel Kapysh on Shutterstock.com
Login to comment